<DOC>
	<DOCNO>NCT00002813</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy cisplatin vinorelbine treat patient refractory recurrent squamous cell cervical cancer respond local therapy .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Recurrent Refractory Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine activity cisplatin vinorelbine term response rate , duration response , time treatment failure , survival patient advance , persistent , recurrent squamous cell carcinoma cervix . OUTLINE : This multicenter study . Patients receive vinorelbine IV 6-10 minute day 1 , 8 , 15 , 22 cisplatin IV 4 hour begin completion vinorelbine infusion day 1 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 28-62 patient accrue study within approximately 20 month .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced , persistent , recurrent squamous cell carcinoma cervix fail local therapy consider incurable Bidimensionally measurable abdominal , pelvic , lesion palpation , x ray , ultrasound If sole site measurable disease previously irradiate , documented disease progression site require PATIENT CHARACTERISTICS : Age : Any age Performance status : GOG 02 Karnofsky 60 % 100 % Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time normal Alkaline phosphatase great 3 time normal Renal : Creatinine great 1.4 mg/dL Creatinine clearance least 50 mL/min creatinine great 1.2 mg/dL Other : No clinically significant infection No preexisting , clinically significant peripheral neuropathy unless due cancer No prior concurrent malignancy except nonmelanomatous skin cancer No psychological , familial , sociological , geographical condition would preclude compliance PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy except radiosensitization Endocrine therapy : Not specify Radiotherapy : See Chemotherapy Recovered toxic effect recent radiotherapy Surgery : Recovered toxic effect recent surgery</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
</DOC>